Journals / The European Research Journal / 2022 / Cilt: 8 - Sayı: 3

Prevalence and clinical significance of serum anti-cyclic citrullinated peptide antibodies in primary Sjögren's syndrome

Pages
347–353
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Acute phaseproteins may be higher in primary SS patients with positive anti-CCP antibody.However, studies have found conflicting findings about the prevalence of erosive arthritis and the future development of RA in these patient groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Although anti-cyclic citrullinated peptide (anti-CCP) antibody is a specific marker for rheumatoid arthritis (RA), it is also detected positively in some other rheumatological diseases including Sjögren's syndrome (SS) and even in healthy people.
📊
Key Findings & Data:This study was conducted to determine the prevalence and clinical significance of serum anti-CCP in primary SS patients followed in our outpatient clinic.Methods: Eighty-two primary SS, 100 RA patients and 100 healthy controls applied to rheumatology outpatient clinic were examined.
💡
Conclusion & Impact:Acute phaseproteins may be higher in primary SS patients with positive anti-CCP antibody.However, studies have found conflicting findings about the prevalence of erosive arthritis and the future development of RA in these patient groups.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Although anti-cyclic citrullinated peptide (anti-CCP) antibody is a specific marker for rheumatoid arthritis (RA), it is also detected positively in some other rheumatological diseases including Sjögren's syndrome (SS) and even in healthy people. Studies have shown that anti-CCP guides the early diagnosis, prognosis and treatment of RA patients. SS and RA overlap syndrome are common. This study was conducted to determine the prevalence and clinical significance of serum anti-CCP in primary SS patients followed in our outpatient clinic.Methods: Eighty-two primary SS, 100 RA patients and 100 healthy controls applied to rheumatology outpatient clinic were examined. Patients and control groups were compared in terms of demographic characteristics, laboratory results and anti-CCP.Results: In the present study, anti-CCP was positive in 4 (4.9%) of 82 primary SS patients. In the SS group, among other autoantibodies, ANA was found to be positive at 88.8%, RF 45%, SS-A 64.6%, and SS-B 36.7%. There was no relationship between anti-CCP and joint involvement in patients with SS.Conclusions: Anti-CCP antibody positivity can be found in SS patients. Acute phaseproteins may be higher in primary SS patients with positive anti-CCP antibody.However, studies have found conflicting findings about the prevalence of erosive arthritis and the future development of RA in these patient groups.

🔖

Cite This Article

KÖŞKER, T. A., DOĞAN, İ., ERTEN, Ş., KÜÇÜKŞAHİN, O. (2022). Prevalence and clinical significance of serum anti-cyclic citrullinated peptide antibodies in primary Sjögren's syndrome. The European Research Journal, Cilt: 8 - Sayı: 3, 347–353. https://ajindex.com/articles/597329

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304
  2. Theander E, Jacobsson LT. Relationship of Sjögren’s syndrome to other connective tissue and autoimmune disorders. Rheum Dis Clin North Am 2008;34:935-47
  3. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93
  4. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing anti-cyclic citrulinated peptide. Arthritis Rheum 2000;43:155-63
  5. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early? A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65
  6. Vincent C, Nogueira L, Clavel C, Sebbag M, Serre G. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 2005;38:17-24
  7. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RWS, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005;34:359-66
  8. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EKL, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 2008;58:1576-81
  9. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8
  10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
  11. Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol 2018;47:141-54
  12. Molano-González N, Olivares-Martínez E, Anaya JM, Hernández-Molina G. Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analy